ARMATA PHARMACEUTICALS, INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic
ARMATA PHARMACEUTICALS, INC. (ARMP) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$172.96 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-25
- ARMATA PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$172.96M.
- ARMATA PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$18.02M.
- ARMATA PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$68.18M.
- ARMATA PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$32.23K.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$172.96M 10-K · filed 2026-03-25 | |
| 2024-12-31 | -$18.02M 10-K · filed 2026-03-25 | |
| 2023-12-31 | -$68.18M 10-K · filed 2025-03-21 | -$68.18K 10-K · filed 2024-03-21 |
| 2022-12-31 | -$32.23K 10-K · filed 2024-03-21 | -$32.23M 10-K · filed 2023-03-16 |
| 2021-12-31 | -$21.71M 10-K · filed 2023-03-16 | |
| 2020-12-31 | -$21.58M 10-K · filed 2022-03-17 | |
| 2019-12-31 | -$18.34M 10-K · filed 2021-03-18 | |
| 2018-12-31 | -$16.70M 10-K · filed 2020-03-19 | -$7.22M 10-K · filed 2019-03-25 |
| 2017-12-31 | -$6.93M 10-K · filed 2019-03-25 | |
| 2016-12-31 | -$6.36M 10-K · filed 2018-03-14 | |
| 2015-12-31 | $1.82M 10-K · filed 2017-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |